Hahnloser D, Petersen G M, Rabe K, Snow K, Lindor N M, Boardman L, Koch B, Doescher D, Wang L, Steenblock K, Thibodeau S N
Division of Colon and Rectal Surgery, Mayo Clinic, Rochester, Minnesota 55905, USA.
Cancer Epidemiol Biomarkers Prev. 2003 Oct;12(10):1023-8.
Genetic susceptibility may play a role in many colorectal cancers (CRCs). Known syndromes such as familial adenomatous polyposis and hereditary nonpolyposis CRC account for <5% of CRCs. The germ-line missense variant of the APC gene, E1317Q, has been proposed to confer a risk for colonic adenomatous polyps (adenomas), but not for CRCs in the general population. These findings are contradictory and controversial. In the present study, 608 cases (377 patients with CRC, 145 patients with 4-100 lifetime adenomas, and 86 with < or =3 lifetime adenomas), and 679 controls (362 spouses and 317 patients with normal colonoscopy) were screened for the APC E1317Q variant. The frequency of heterozygotes for E1317Q among patients with CRC (2.4%), patients with 4-100 adenomas (1.4%), and < or =3 adenomas (3.5%) did not differ from spouse controls (2.8%). When CRC patients were examined by DNA mismatch repair status, age at onset (< or =age 50 versus >50), or family history of CRC, no differences in the frequency of E1317Q were found. The APC variant E1317Q does not appear to be associated with increased risk for colorectal neoplasia in the general population. However, when we used normal colonoscopy controls (E1317Q carrier frequency = 0.3%), the prevalence of E1317Q was significantly increased in CRC patients, in patients with < or =3 adenomas, and in CRC patients with intact mismatch repair status, suggesting a possible role for E1317Q in colorectal tumorigenesis. These results underscore the importance of carefully defining the controls to be used in comparisons of allele frequencies.
遗传易感性可能在许多结直肠癌(CRC)中起作用。已知的综合征,如家族性腺瘤性息肉病和遗传性非息肉病性结直肠癌,占结直肠癌的比例不到5%。APC基因的种系错义变体E1317Q已被提出会增加结肠腺瘤性息肉(腺瘤)的风险,但在一般人群中不会增加患结直肠癌的风险。这些发现相互矛盾且存在争议。在本研究中,对608例病例(377例结直肠癌患者、145例一生中患4 - 100个腺瘤的患者和86例一生中患≤3个腺瘤的患者)以及679名对照(362名配偶和317名结肠镜检查正常的患者)进行了APC E1317Q变体筛查。结直肠癌患者(2.4%)、患4 - 100个腺瘤的患者(1.4%)和≤3个腺瘤的患者(3.5%)中E1317Q杂合子的频率与配偶对照(2.8%)没有差异。当根据DNA错配修复状态、发病年龄(≤50岁与>50岁)或结直肠癌家族史对结直肠癌患者进行检查时,未发现E1317Q频率存在差异。APC变体E1317Q似乎与一般人群中结直肠肿瘤形成风险增加无关。然而,当我们使用结肠镜检查正常的对照(E1317Q携带者频率 = 0.3%)时,E1317Q在结直肠癌患者、≤3个腺瘤的患者以及错配修复状态完整的结直肠癌患者中的患病率显著增加,这表明E1317Q在结直肠癌发生中可能起作用。这些结果强调了在比较等位基因频率时仔细定义所使用对照的重要性。